Background: Curcuma longa has biological effects. Its cardiovascular activities are yet to be scientifically studied.
Introduction
According to the World Health Organization (WHO) and the Pan American Health Organization (PAHO), heart diseases are one of the major causes of death worldwide1 and in low-and middle-income countries, more than three-quarters of the deaths are due to cardiovascular diseases. 1, 2 Hypertension is the main risk factor for the development of cardiovascular diseases, affecting more than one billion people worldwide. [3] [4] [5] The use of allopathic drugs has been the main type of therapy used to fight hypertension and, consequently, all the other diseases that result from it, even though it is known that one of the major problems of this treatment option are its side effects. 5 Recently, more attention has been paid to the use of medicinal plants to attenuate the damage of several diseases, including arterial hypertension. 6, 7 The rhizome of Curcuma longa Linnaeus, which belongs to the Zingiberaceae family of Malay-Indigenous origin, 8 popularly known as Yellow Ginger or Saffron, was used only as a food dye in many countries, and its Original Article leaves were used to wrap fish and to give aroma and flavor to the food preparation. 9 More recent studies report cardioprotective, 10 anti-inflammatory, 8, 11 antimicrobial, 12 antiproliferative, 12 antioxidant, 13 antifungal 14 and vasorelaxant 15 properties. There is still little available information on its mechanism of action and effects on the cardiovascular system. The present study aims to investigate AECL action on vascular contractions induced in the isolated aortic artery of normotensive rats. Preclinical scientific studies of this nature may not only serve as the basis to obtain alternative phytomedicinal sources of attenuation of cardiovascular system-related diseases among the traditional needy populations, but they can, primarily, indicate to the scientific community and to the pharmaceutical industry new sources of raw materials to obtain medicinal principles available in nature, which already have discreet and crucial scientific information.
Methods

Preparation of the Curcuma longa L extract
The plant was collected in a private property located in Vila Campinas, Ramal das chácaras, in the municipality of Plácido de Castro, in the state of Acre, northern Brazil. A voucher specimen was deposited at the herbarium of Universidade Federal do Acre (UFAC), under number 20002. The healthy-looking leaves were selected, washed under running water and placed in a greenhouse at 40°C for 48 hours, where dehydration occurred, and then they were ground in a knife-type mill at the Food Technology Unit (UTAL) of Universidade Federal do Acre. To obtain the aqueous extract of Curcuma Longa (AECL), 4 liters of distilled water with 370 grams of the crushed plant material were placed in a heated balloon flask for 10 minutes at 100°C, followed by filtration. The filtrate was lyophilized, stored in an amber glass vial and kept under refrigeration at 4°C.
Drugs
Phenylephrine hydrochloride (PHE), atropine sulfate, acetylcholine chloride (ACh), NG-nitro-L-argininemethyl ester (L-NAME) and Indomethacin were used, all from SIGMA-ALDRICH. Stock solutions of indomethacin were dissolved together with 5 N sodium bicarbonate (NaHCO 3 ) in distilled water. The other drugs, including AECL and solutions, were diluted in distilled water. The perfusion medium used was Krebs-Henseleit nutrient solution, containing (in mM): NaCl (118.4); KCl (4.75); KH 2 PO 4 (1.18); NaHCO 3 (25) ; MgSO 4 (1.18); CaCl 2 (1.9) and glucose (5) . The nutrient solution had the pH adjusted with 1M HCl or 1M NaOH to 7.3 and 7.4. The AECL concentrations that were cumulatively used in all experiments were, invariably, 1, 3, 10, 30, 100, 300 and 1000 μg/mL. PHE and ACh concentrations were 0.1 μM in all experimental protocols.
Toxicity Assay
To assess possible toxic effects of the AECL, a Fixed Dose Procedure (FDP) parameter was used according to the Acute Toxic Class Method of 2001 (OECD). 16 In this test, mice fasted for 12 hours prior to the experiment and were divided into 3 groups (n sample = 6, used for convenience): group 1 (control), 2 (dose of 2000 mg/kg) and 3 (dose of 5000 mg/kg), comprising a total number of 18 animals. Only saline solution was administered in group 1, and in group 2, the dose of 2000 mg/kg. In the absence of lethality or toxicity, then the dose of 5000 mg/kg was administered in group 3. The toxicity assessed by observing the following behavioral parameters, described in the hippocratic test of Malone and Robichaud 17 are: attention, alertness, analgesia, spontaneous motor activity, locomotion, lack of appetite, apathy, response to tact, piloerection, ptosis, respiratory rate, cyanosis, stereotypy, contortion, aggressiveness, ataxia, posture, sweating, urination, diarrhea and seizure.
The parameters were observed every 60 minutes for 3 hours after the administration of the extract. Subsequently, they were also observed after 24, 48, and 72 hours and on the 15 th day. At the end of the observations all the animals were euthanized according to the euthanasia practice guidelines of the National Council for the Control of Animal Experimentation (Conselho Nacional de Controle de Experimentação Animal -CONCEA). Traditional barbiturates and anesthetics were used for the euthanasia procedure, with a rapid, gentle effect and with minimal discomfort to the animals. These drugs are potent Central Nervous System depressants, of which effects are widely known and predictable.
Assessment of AECL activity in the annuli of isolated thoracic aorta of rats
A total of 14 rats were used in this study, resulting in 42 aortic annuli. Initially the annuli were divided into Original Article two groups (n = 6), being sufficient to perform in vitro experiments for each concentration of the same group with the same nature, defined as group 1 (annulus with present endothelium) and 2 (annulus without endothelium). Subsequently, the subgroups were divided into five groups (n = 6) for the assessment of the verified action mechanism, namely: group 1.1 (L-NAME), group 1.2 (Indomethacin), group 1.3 (Atropine), group 2.1 (KCl 20) and group 2.2 (KCl 80).
Preparation and setting-up of the vascular annulus
Male rats of the Rattus norvegicus species, of the Wistar lineage, weighing 200-300 g, were euthanized by cervical dislocation and then a ventral incision was performed with opening of the rib cage by performing an excision in the sternum and part of the ribs, for visualization and removal of the intrathoracic organs. The thoracic aorta was removed and transferred to a Petri dish containing Krebs nutrient solution aerated by carbogenic mixture (95% CO 2 + 5% O 2 ) and cleansed by removing the adipose tissue and connective tissue adhered to the artery segment. The artery segment was fractionated into 4 mm-rings and set up, fixed between 2 small wire triangles. One side of one of the triangles was introduced into the annulus lumen, with the vertex opposite to the annulus, being fixed to the base of a thin metallic rod attached to the system, and the opposite vertex of the other triangle, by a cotton thread, attached to a isometric force transducer (AdInstruments).
The aorta preparations for all experiments were preliminarily stabilized for 1 hour in Krebs nutrient solution, with replacement of the solution every 15 minutes to eliminate and minimize metabolite effect; constant adjustment of the passive voltage applied to the annulus was also performed to 1 g (baseline initial tension), maintained at 37°C and continuously aerated by carbogen (95% O 2 + 5% CO 2 ). The data on voltage variations, as a function of tissue reactivity to drug administration, were obtained after the conversion of the electrical signals captured by the transducer into digital signals and transmitted by an amplifier-recorder (AdInstruments). The variation records of the degree of contraction of the annulus smooth musculature were sent to a microcomputer, where they were processed and stored in the Protowin organ baths software (Pan Lab) for later analytical and statistical treatment.
All protocols were carried out according to the norms issued by the National Council for the Control of Animal Experimentation (CONCEA) and approved by the Ethics Committee on Animal Use (Comitê de Ética no Uso de Animais -CEUA) of UFAC (Universidade Federal do Acre) under number 23107.018498 / 2016-40.
Evaluation of the AECL activity in aortic annuli with and without endothelium contracted with phenylephrine
Immediately after the preparations' stabilization period, the presence (E + ) or absence (E-) of functional endothelium in the annuli was verified by adding ACh on the plateau of the sustained tonic phase of the PHEinduced contraction, establishing as (E + ) annuli those of which relaxation percentages induced by ACh were ≥ 70% and as (E-), those with < 5% of relaxation. The tissues prepared in the recipients were again contracted by PHE and, after five to seven minutes of sustained tonic phase contraction, increasing concentrations of AECL (1, 3, 10, 30, 100, 300 and 1000 μg/mL) were cumulatively added to the preparations containing (E + ) or (E-) annuli. The relaxation percentage was determined by comparing the PHE contraction values before and after the cumulative addition of the extract and also by calculating the EC50 values.
Evaluation of the AECL effect after inhibition of the enzymes of the nitric oxide (NO) production pathway, the prostacyclin (PGE2 and PGI2) production pathway and the endothelial muscarinic blockade
In annulus-containing preparations (E + ), the cumulative administration of AECL at the PHE-induced contraction plateau was performed before and after the L-NAME (100 μM), and incubated for 30 minutes, for the evaluation of nitric oxide (NO) involvement in the AECL effect. To assess the involvement of prostacyclines, indomethacin (10 μM), instead of L-NAME, was also incubated for 30 minutes. To verify the probable participation of muscarinic receptors, following the same experimental protocol, atropine incubation (1 μM) was previously performed for 15 minutes, instead of the two enzyme inhibitors.
Evaluation of AECL activity in contracted aortic rings with depolarizing KCl solution
To evaluate the involvement of ion channels, experiments were performed using (E-) annuli. In these approaches, after stabilization of the preparations and other mandatory preliminary procedures, instead of 
Statistical analysis
All points plotted in the graphs are expressed as mean ± standard deviation (SD) and represent the individual experiments (control and treatments) (n sample = 6, by convenience) for each one of them, performed individually. The nature of biological responsiveness and the biochemical processes triggered by the injection of exogenous substances and the reactivity due to the induction of endogenous releases, as well as considering the very nature of the crude extracts (consisting of many active principles), naturally justify the fact that the EC 50 values resulting from the analyses on individual concentration-response curves were carried out through non-linear regression. The D'Agostino normality test was performed. As the data were normal, the two-way analysis of variance (ANOVA) was applied. Statistical differences between the means of the results were determined by the paired Student's t test and when appropriate (for multiple comparisons). The authors did not observe limiting factors in this study. The analyses and representations were carried out with the software GraphPad Prism 6.0 (GraphPad Software Inc., San Diego, CA, USA), with significance being set at p < 0.05.
Results
Toxicity
None of the animals died or showed deleterious behavioral changes capable of compromising the limits of normality during the toxicity studies (data not shown). The group receiving the 2000 mg/kg dose, even up to the fifteenth day of observation, showed no alterations as a result of the treatment. At the dose of 5000 mg/kg there was mild sedation in the first hour after the extract administration in only one animal in the group. At the subsequent hours and days, none of the animals showed any behavioral change or died. Therefore, AECL did not show any alterations of clinical importance in the animals submitted to the treatments.
Influence of the vascular endothelium on AECL activity in isolated aortic artery annuli of normotensive rats pre-contracted with PHE
In E + annuli, the AECL abolished contractions induced by PHE, with an EC 50 = 4.32 ± 0.05 μg/mL. Significant vasorelaxation (p < 0.01) occurred in a concentrationdependent manner. In the E-annuli, it also reached 100%, but the AECL response was significantly (p < 0.01) modified by the removal of the vascular endothelium and EC 50 increased to 134.20 ± 1.80 μg/mL, indicating that the effect of AECL strongly depends on factors derived from the vascular endothelium ( Figure 1 ).
Involvement of NO in the AECL relaxant effect on isolated aortic artery annuli of normotensive rats pre-contracted with PHE
After inhibition of the NO synthesis enzyme by L-NAME, the AECL vasorelaxant effect on intact aorta annuli was significantly (p < 0.01) inhibited, an event evidenced by an increase in the EC 50 , from 4.32 ± 0.05 μg/mL to 126.50 ± 2.35 μg/mL (Figure 2) , indicating clear involvement of the NO production pathway in the AECL effect.
Involvement of the prostacyclin production pathway in the AECL relaxant effect on isolated aortic artery annuli of normotensive rats pre-contracted with PHE
After blocking prostaglandin synthesis with indomethacin, the vasorelaxant response induced by AECL was significantly (p < 0.01) inhibited after indomethacin incubation, a fact disclosed by the EC 50 elevation, from 4.32 ± 0.05 μg/mL to 124.6 ± 0.05 μg/mL), suggesting that the AECL effect is also related to the prostacyclin production pathway (Figure 3 ).
Involvement of the muscarinic pathway in the AECL relaxant effect on isolated aortic artery annuli of normotensive rats pre-contracted with PHE
In this approach, the vasorelaxant response induced by AECL was the most significantly attenuated, as shown by the prominent (p < 0.01) increase in EC 50 , from 4.32 ± 0.05 μg/mL to 437.10 ± 0.2 μg/mL (Figure 4) . These data suggest that, of the investigated pathways, muscarinic receptors seem to be the most significantly implicated in the vasorelaxant effect induced by the AECL on the isolated thoracic aorta of rats. CLAE (1, 3, 10, 30, 100, 300 and 1000 CLAE (1, 3, 10, 30, 100, 300 and 1000 CLAE (1, 3, 10, 30, 100, 300 and 1000 CLAE (1, 3, 10, 30, 100, 300 and 1000 CLAE (1, 3, 10, 30, 100, 300 and 1000 
AECL effect on the contraction caused by blocking the intracellular K + efflux
In annuli without endothelium, although with much less significance, the AECL continued to show a significant vasorelaxant activity (p < 0.01). The AECLinduced response in the isolated thoracic aortic annuli of rats precontracted with 20 mM KCl was significantly (p < 0.01) lower than the AECL-induced vasorelaxation on PHE-induced contraction in (E-) annuli ( Figure 5 ). The percentage of vasorelaxation over the 20 mM KCl contraction was 56.98% and 31.56%, over the 80 mM KCl contraction. Therefore, it seems that the effect of AECL has a greater significance for the opening of K + channels than for the blockade of voltage-operated calcium channels (VOCCs) ( Figure 5 ).
Discussion
In the first approach (Figure 1) with (E + ) and (E-) annuli, it was observed that the AECL effect strongly depends on factors derived from the vascular endothelium, due to its greater relaxation in E + annuli.
The vascular endothelium, through the layer of cells that covers it internally, produces different mediating substances that regulates the vascular smooth muscle tone. [18] [19] [20] [21] [22] [23] There is a natural control of these mediators' release, and at the limit of the physiological functions, the release of the relaxant factors precedes the contracting agents, 19 of which NO is the first to be released, followed by prostacyclin and other endothelium-derived relaxant agents. 20 In many studies, the NO produced by endothelial cells with physiological vasodilation function 21, 22 has been indicated as the main relaxant factor derived from the vascular endothelium. It crosses space from the endothelium to the vascular smooth muscle, promoting the relaxation of this musculature cells, 23 acting by stimulating the guanylyl cyclase of the cytoplasm soluble fraction, converting Guanosine triphosphate (GTP) into cyclic Guanosine Monophosphate (cGMP), which is the second messenger responsible for the vascular relaxant effect. 24 In the NO synthesis, first the hydroxylation of one of the guanidine nitrogens of L-arginine occurs to generate NG-hydroxy-L-arginine (NHA), followed by the conversion of NHA into NO and citrulline. 25 (L-NA) and the corresponding methyl ester, NG-nitro-L-arginine-methyl ester (L-NAME). 26 These analogues compete with L-arginine and act as stereospecific inhibitors of NOS. 21 After the blockade of NO production (Figure 2) , it was verified that during the AECL effect there is an important involvement of NO in the vasorelaxant effect production. In addition to the involvement of NO in the AECL effect, it is scientifically obligatory to investigate the participation of other pathways in relation to the observed effects, especially since it is a crude extract and, thus, a compound consisting of many substances. Therefore, it is possible to suggest that other endothelium-derived vasorelaxant pathways and other independent ones may also be involved in the AECL vasorelaxant activity.
The prostaglandins are synthesized from the arachidonic acid, which is released from the phospholipids of the endothelial cell membrane by the activated phospholipases (A2 and C), and through the action of cyclooxygenase enzymes (COX-1 and COX-2). 27 Once released, primarily PGI2 and PGE2, they diffuse into smooth muscle cells, promoting the vasorelaxant effect through IP and EP4 receptors, increased cAMP and by reducing intracellular Ca 2+ . 28 The blockade of vasorelaxant prostaglandins synthesis occurs through the inactivation of arachidonic aciddegrading enzymes (COX-1 and COX2). 27 Indomethacin is a non-selective inhibitor of these prostaglandins. 29 In the presence of this blockade and the reduction of the vasorelaxant effect produced by the extract (shown in Figure 3 ), it is also possible to suggest the involvement of prostaglandins.
The muscarinic receptors are also present in the vascular endothelium; they can be found in many cell types and participate in cell signaling as soon as they are activated by the ligand acetylcholine. 30 There are five subtypes of muscarinic receptors that are currently accepted, namely M1, M2, M3, M4 and M5, with the M3 receptors being the ones that contribute to smooth muscle contraction, glandular secretion and endothelial NO secretion. It is through the production of endothelial NO that ACh has vasodilatory effects in vivo. 31 Aiming to verify the involvement of the muscarinic pathway in the AECL relaxant effect, the antagonism of the muscarinic receptors was performed through incubation with atropine, a muscarinic receptor antagonist that acts through competitiveness in these receptors, preventing ACh from binding and exercising its activity. In this approach (Figure 4) , where the vasorelaxant response of AECL was more attenuated, muscarinic receptors seem to be the most significantly implicated (p < 0.01) in the vasorelaxant effect induced by the AECL in the isolated thoracic aorta of rats.
The relaxant response in annuli (E-) was also important in these approaches to evaluate the possible involvement of ion channels. The activity of K + channels is an essential mechanism for the regulation of the vascular muscle cell membrane potential, being an important determinant of vascular tone. 32 The opening of a potassium channel present in the membrane of vascular muscle cells causes an increase in ion output, from the intracellular medium into the extracellular medium, causing cell membrane hyperpolarization and then a blockade of voltagedependent Ca 2+ channels and a consequent decrease in the input of Ca 2+ ions into the intracellular medium, causing vascular relaxation. 32, 33 Conversely, the closing of potassium channels causes a state of depolarization, opening of voltage-dependent Ca 2+ channels, increase in intracellular Ca 2+ and vasoconstriction. 32 This mechanism of smooth-muscle relaxation and contraction differs regarding the PHE mechanism of action, which directly stimulates the α-adrenergic receptors of the G protein, acting via phospholipase C, increasing the levels of IP3, and resulting in the release of intracellular Ca 2+ , causing muscular contraction. 34 These results, shown in Figure 5 , demonstrate that part of the AECL relaxant effect is related to the influence that the extract seems to have on the opening of ion channels, especially K + channels, since the hyperpolarization of the smooth muscle cell membrane can be produced by agents that open the K + channels, leading to the cell's K + efflux. 35 K + -induced contraction in the aorta seems to be dependent on the influx of Ca 2+ through VOCCs, whereas the contraction is inhibited by the removal of Ca 2+ from the external environment and by the blockers of these channels. 36 At the same time that the opening of Ca 2+ channels may be required by a membrane depolarization process, the agents that produce membrane hyperpolarization can cause the Ca 2+ channels to close, reducing the Ca 2+ influx and promoting smooth muscle relaxation. 37 Ionic channels also seem to be involved in the AECL significant vasorelaxant activity, with a greater expression in the opening of K + channels than in the blockade to VOCCs. 
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Conclusion
The AECL induced an important vasorelaxant effect, being more significant in the presence of the endothelium. The muscarinic pathway seems to be the main one involved with this effect, followed by the NO production pathway, the Prostacyclin's. The opening of K + channels by the AECL, although with a prominently lower degree of participation when compared to the retro-reported pathways, seems to have greater expression than its blockade to VOCCs. AECL showed no evidence of toxicity at the administered concentrations. Further studies are needed on the phytochemistry of AECL, as well as better pharmacological investigation through many other approaches and experimental models, including the use of tools to elucidate the action mechanisms of the extract.
